Novo Nordisk and Hims & Hers have come to an agreement that will see the telehealth company sell Novo’s branded glucagon-like peptide-1 receptor agonists (GLP-1RAs), ending a long-running feud that had spiralled into legal proceedings.

As per the collaboration, Hims & Hers will sell Novo’s semaglutide brands, Ozempic and Wegovy, at various doses. Wegovy will be available in both injectable and oral form – the latter owing to Novo’s recent US Food and Drug Administration (FDA) approval. The branded products will be available at the same self-pay prices as other telehealth platforms. Hims & Hers will continue to offer compounded semaglutide, but only on a limited scale.

In return for offering its branded GLP-1RAs, Hims & Hers will no longer advertise compounded versions on its platform or in its marketing, and existing patients will have the opportunity to transition to FDA-approved medicines when determined clinically appropriate by their providers. Compounded semaglutide will remain available only in cases where personalised dosing is needed.

Novo’s CEO Mike Doustdar said: “By expanding access through leading telehealth providers and digital care platforms, we are helping to connect more people with our FDA-approved medicines, which have been evaluated for safety and efficacy.”

Hims & Hers’ CEO Andrew Dudum said: “We see tremendous growth opportunities in the US with the expanding assortment of branded GLP-1RA medications. I’m excited to have a great partner in Novo Nordisk as we work to create a new model that works for everyday people.”

Feud ends for now

The partnership brings an end to a long-running feud between Novo and Hims & Hers in the GLP-1RA market. Novo has had to battle erosion in the obesity market amid pressure from drugs developed by Eli Lilly and compounded products being sold by telehealth providers such as Hims & Hers.

In April 2025, the two companies tried to settle their differences with an alliance. Novo Nordisk partnered with the telehealth company to offer Wegovy at a discounted price on the Hims & Hers platform, distributed via the pharma’s online pharmacy NovoCare. Less than two months later, Novo terminated the agreement after accusing Hims & Hers of failing to adhere to the law – highlighting the continued selling of compounded semaglutide.

The feud came to a head in February 2026, when Novo sued Hims & Hers after the latter announced plans to sell the Wegovy pill. The development stirred regulators at the FDA too – commissioner Marty Makary announced the agency would crackdown on illegal copycat drugs. Hims & Hers swiftly abandoned its Wegovy pill strategy in the face of legal proceedings and regulatory action. As a result of the current partnership, Novo said it has dismissed its patent infringement lawsuit, though it did rule out a refile in the future.

Reacting to the agreement, Citi analysts said: “We see upside as limited given Hims & Hers sales of compounded GLP-1RA were limited and FDA was working to remove them from the market anyway.”

In a social media post, Makary said he was “glad to see that Hims & Hers will stop advertising unapproved compounded drugs and instead sell FDA-approved products through its new partnership with Novo Nordisk”.

The GLP-1RA sector has changed significantly over the last year in the US, primarily due to pricing reforms. Both Novo and Eli Lilly inked pricing agreements with President Trump in November 2025 that saw the costs of their branded obesity drugs slashed. In February 2026, the White House launched TrumpRx, a direct-to-consumer (DTC) channel that offers weight loss drugs at discounted prices.